Ari Rosenberg, MD, University of Chicago Medical Center, Chicago, IL, discusses the Phase I trial (NCT01847326) of nab-paclitaxel-based induction therapy followed by nab-paclitaxel-based chemotherapy and re-irradiation for patients with previously-treated head and neck cancer. The primary endpoints were maximum dosage and dose-limiting toxicity of nab-paclitaxel when combined with the FHX regimen (5-fluorouracil, hydroxyurea, and twice-daily radiation). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). The recommended Phase II dosage was determined to be 100mg/m2. 23% of patients saw a 4-year PFS and 26% achieved OS. The PFS and OS rates were higher in patients responding to induction chemotherapy and were then treated with chemo-irradiation. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.